Sickle cell disease (SCD) patients ending with mixed mononuclear chimerism after non-myeloablative HSCT with alemtuzumab/TBI conditioning will probably preserve their immune response to vaccinations administered prior to the transplantation and will therefore not need to be revaccinated. Furthermore, SCD patients after haploidentical HSCT might benefit from adoptive transfer of immunity from their donors.
To test the first hypothesis, patients undergoing alemtuzumab/TBI HSCT will be vaccinated with a hepatitis B virus (HBV) vaccine before the transplant. To test the second hypothesis, haploidentical and matched related donors will be vaccinated prior to stem cell donation against HBV. Neither the patient nor the donor may previously have been immunized against HBV in all cohorts. Post-transplantation, the investigators will be able to evaluate whether SCD patients preserve their pre-transplant immune response in the post-transplantation period. Furthermore, the investigators will determine whether donors transfer their immunity to HSCT recipients with SCD disease.
| Erfan Nur, MD, PhD | |
| 0031-20-4442604 | |
| [email protected] |
| Management hematology | |
| 0031-20-4442604 | |
| [email protected] |
16 Years - 60 Years
Not Applicable
Interventional
All
Drug
Age 18 or older
High performance liquid chromatography (HPLC) confirmed diagnosis of SCD (not applicable to participating donors).
An indication for and a planned matched sibling or haploidentical donor non-myeloablative HSCT at the Amsterdam UMC, location AMC (not applicable to patients in cohort 2 (control group) and participating donors)
Written informed consent
History of either cleared, chronic or active HBV infection (positive HBsAg, anti-HBs, anti-HBc and/or HBV DNA)
History of auto-immune diseases and/or use of immunosuppressive drugs
History of HIV infection
Known hypersensitivity to yeast of any vaccine constituent
Donor with a history of HBV infection